News Transcenta Holding Limited

Equities

6628

KYG9005B1041

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.78 ^HKD	+1.71%		+5.95%	-50.42%

Apr. 09	Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	MT
Apr. 09	Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	Apr. 09	MT
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial	Apr. 08	CI
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal	Dec. 13	MT
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging	Dec. 13	CI
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet	23-10-23	MT
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain	23-10-23	CI
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment	23-10-03	MT
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients	23-10-03	CI
Transcenta Widens Loss in H1	23-08-23	MT
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023	23-08-22	CI
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Transcenta Moves to Phase II Trial of Osteoporosis Drug	23-07-31	MT
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)	23-07-30	CI
China, South Korea Approve Transcenta's Phase 3 Trial for Anti-Tumor Medication	23-07-07	MT
Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab	23-07-07	CI
Transcenta Holding Limited Presents Pfs Data by Cldn18.2 Expression Level from Phase I/Ii Study of Osemitamab Plus Capecitabine and Oxaliplatin as the First-Line Treatment of Advanced G/Gej Cancer	23-06-30	CI
Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin	23-06-30	CI
Transcenta Holding Limited commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on June 9, 2023.	23-06-09	CI
Transcenta Holding Limited's Equity Buyback announced on September 14, 2022, has expired.	23-06-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Transcenta Holding Limited

Equities

6628

KYG9005B1041

Summary

Filters